000 02122nam  2200325zi 4500
0019.917914
003CaOODSP
00520230104110146
006m     o  d f      
007cr mn|||||||||
008221201e20220614onca    ob   f000 0 eng d
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aYN5-258/2022E-PDF
24500|aCanadian patented drug prices : |bgauging the change in reference countries.
264 1|a[Ottawa] : |bOffice of the Parliamentary Budget Officer = Bureau du Directeur parlementaire du budget, |cJune 14, 2022.
264 4|c©2022
300 |a1 online resource (20 pages) : |bcolour illustrations
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Prix canadiens des médicaments brevetés : mesurer l'importance de la modification dans les pays de référence.
500 |a"RP-2223-008-S_e."
504 |aIncludes bibliographical references.
520 |a"The Parliamentary Budget Officer (PBO) supports Parliament by providing economic and financial analysis for the purposes of raising the quality of parliamentary debate and promoting greater budget transparency and accountability. Regulatory changes for how the Patented Medicines Prices Review Board (PMPRB) formulates price ceilings for patented drugs have been proposed and are due to come into effect in July of 2022. This report examines the proposed change and quantifies its long-term impact. We find that a change to the median of eleven comparator countries is important, but that more flexibility to re-adjust prices would potentially contribute more to reducing expenditures by Canadians."
650 0|aPatent medicines|xPrices|zCanada.
650 0|aPatent medicines|xPrices|xLaw and legislation|zCanada.
7101 |aCanada. |bOffice of the Parliamentary Budget Officer, |eissuing body.
77508|tPrix canadiens des médicaments brevetés : |w(CaOODSP)9.917915
85640|qPDF|s318 KB|uhttps://publications.gc.ca/collections/collection_2023/dpb-pbo/YN5-258-2022-eng.pdf